Brean Murray downgraded Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) from Hold to Sell with a $7 price target, saying they are ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE